Eliem Therapeutics Q3 net loss $9.7M, cash $129.6M; ETX-155 Phase 2a MDD trial to start Q1 2023

Climb Bio, Inc.

2022-Q3 EPS reported -$1.43

Net loss of $9.7M for Q3 2022 (vs. $9.6M Q3 2021); R&D expenses $4.3M, G&A $4.5M.
Cash and marketable securities $129.6M as of Sep 30, 2022; cash runway expected to fund operations into 2025.
ETX-155 Phase 2a MDD trial to initiate in Q1 2023 with 60-mg dose; topline data expected H2 2024.
Kv7.2/3 program: IND-enabling safety studies for two pre-candidates expected Q1 2023; Phase 1 studies planned H1 2024.
Phase 1 PK trial completed; selected 60-mg dose over 75-mg due to marginal additional benefit.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Climb Bio, Inc. reported the quarter ended September 30, 2022 results: net income $9.7 million.

Period: the quarter ended September 30, 2022
Net income: $9.7 million
Result: reported results

Exact text from the filing

Net loss was $9.7 million for the three months ended September 30, 2022, compared to $9.6 million for the same period in 2021.

View on SEC.gov

51 earnings releases filed in the last 30 days. Browse all earnings releases →

Climb Bio, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-22-024621

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.